TTKHLTCARE
TTK Healthcare share price & financials
- Price
- ₹929.4
- Market cap
- ₹1.6k Cr
- Sector
- Diversified
What TTK Healthcare Limited does
TTK Healthcare is a diversified manufacturer operating across five reported segments - Consumer Products, Animal Welfare, Medical Devices, Protective Devices and Foods - running 8 factories across Tamil Nadu, Kerala, Karnataka, Rajasthan and Puducherry. It makes personal and home-care brands such as Woodward's Gripe Water, EVA and Good Home, animal-health products for livestock, poultry and pets under the Bovianim, Gallus and Companim ranges, and TTK Chitra mechanical heart valves plus Buechel-Pappas orthopaedic knee and hip implants through its Medical Devices business. Its Protective Devices business manufactures and markets Skore condoms - it is a pre-qualified supplier under the WHO-UNFPA scheme for male latex condoms - alongside the digital pleasure-products platforms Love Depot and MsChief, while its Foods Division makes ready-to-fry snack pellets at plants in Hosakote (Karnataka) and Jaipur (Rajasthan). The company divested its Human Pharma business via a slump sale in FY2022-23 and now operates through these five continuing segments.
Segments
- Consumer Products
- Animal Welfare
- Medical Devices
- Protective Devices
- Foods
- Reported business segments
- 5
- Manufacturing facilities (factories)
- 8
- Manufacturing footprint (states)
- Tamil Nadu, Kerala, Karnataka, Rajasthan, Puducherry
- Heart valve technology
- TTK Chitra - India's first and only indigenous mechanical heart valve prosthesis, manufactured at the Trivandrum (Kerala) facility
- Orthopaedic implant range
- Buechel-Pappas mobile-bearing knee system (technical collaboration with BP Trust, USA) plus hip, revision-knee and cemented/cementless implant lines
- Condom export qualification
- Pre-qualified supplier under the WHO-UNFPA Pre-Qualification Scheme for male latex condoms
Quarterly results
Q1 FY27: revenue up 14.2%, net profit up 61.5% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 198 | 205 | 190 | 226 | 204 +3% | 209 +2% | 218 +15% | 258 +14% |
| EBITDA | 8 | 8 | 12 | 3 | 5 −37% | 7 −12% | 11 −8% | 15 +400% |
| Net profit | 17 | 17 | 16 | 13 | 20 +18% | 11 −35% | 22 +38% | 21 +62% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −2.9% 1Y
1Y: ₹1,148.9 on 10 Sept 2025 → ₹1,115.4. High ₹1,192.6 (21 Oct 2025), low ₹739.6 (30 Mar 2026).
Financials, as filed
Revenue grew 5.7% a year over 3 years, FY23 to FY26. Operating margin narrowed to 3.0%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹726 Cr | ₹753 Cr | ₹801 Cr | ₹857 Cr |
| Operating profit | ₹31 Cr | ₹37 Cr | ₹35 Cr | ₹26 Cr |
| Operating margin | 4.3% | 4.9% | 4.4% | 3.0% |
| Interest | ₹6 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr |
| Depreciation | ₹12 Cr | ₹12 Cr | ₹8 Cr | ₹8 Cr |
| Net profit | ₹640 Cr | ₹63 Cr | ₹82 Cr | ₹66 Cr |
| Net margin | 88.2% | 8.4% | 10.2% | 7.7% |
| Cash from operations | ₹-25 Cr | ₹-5 Cr | ₹-4 Cr | ₹-21 Cr |
| Free cash flow | ₹-36 Cr | ₹-15 Cr | ₹6 Cr | ₹-25 Cr |
| ROCE | 10.0% | 9.0% | 9.0% | 8.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr |
| Reserves | ₹281 Cr | ₹316 Cr | ₹939 Cr | ₹987 Cr | ₹1.1k Cr | ₹1.1k Cr |
| Borrowings | ₹19 Cr | ₹22 Cr | ₹27 Cr | ₹23 Cr | ₹27 Cr | ₹24 Cr |
| Other liabilities | ₹180 Cr | ₹207 Cr | ₹189 Cr | ₹183 Cr | ₹184 Cr | ₹190 Cr |
| Total liabilities | ₹494 Cr | ₹559 Cr | ₹1.2k Cr | ₹1.2k Cr | ₹1.3k Cr | ₹1.3k Cr |
| Fixed assets | ₹85 Cr | ₹80 Cr | ₹71 Cr | ₹75 Cr | ₹78 Cr | ₹73 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹3 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr |
| Investments | ₹13 Cr | ₹15 Cr | ₹13 Cr | ₹13 Cr | ₹12 Cr | ₹9 Cr |
| Other assets | ₹395 Cr | ₹463 Cr | ₹1.1k Cr | ₹1.1k Cr | ₹1.2k Cr | ₹1.2k Cr |
| Total assets | ₹494 Cr | ₹559 Cr | ₹1.2k Cr | ₹1.2k Cr | ₹1.3k Cr | ₹1.3k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, DIIs added +1.01 pp while the public trimmed −0.98 pp. The shareholder count grew 42% to 22,809.
- Promoters
- 74.6%
- FIIs
- 1.9%
- DIIs
- 2.2%
- Public
- 21.4%
Since Jun 2025
- DIIs +1.01 pp
- Public −0.98 pp
- FIIs −0.03 pp
How it drifted, 12 quarters
Over this window DIIs fell from 3.2% to 2.2% — −1.0 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 74.6%, FIIs 1.9%, DIIs 3.2%, Public 20.4%.Dec '23: Promoters 74.6%, FIIs 1.9%, DIIs 3.1%, Public 20.5%.Mar '24: Promoters 74.6%, FIIs 1.9%, DIIs 1.1%, Public 22.4%.Jun '24: Promoters 74.6%, FIIs 1.9%, DIIs 1.1%, Public 22.4%.Sep '24: Promoters 74.6%, FIIs 1.9%, DIIs 1.1%, Public 22.4%.Dec '24: Promoters 74.6%, FIIs 1.9%, DIIs 1.1%, Public 22.4%.Mar '25: Promoters 74.6%, FIIs 1.9%, DIIs 1.1%, Public 22.4%.Jun '25: Promoters 74.6%, FIIs 1.9%, DIIs 1.2%, Public 22.4%.Sep '25: Promoters 74.6%, FIIs 1.9%, DIIs 1.2%, Public 22.4%.Dec '25: Promoters 74.6%, FIIs 1.9%, DIIs 1.1%, Public 22.5%.Mar '26: Promoters 74.6%, FIIs 1.9%, DIIs 1.1%, Public 22.4%.Jun '26: Promoters 74.6%, FIIs 1.9%, DIIs 2.2%, Public 21.4%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Abakkus Diversified Alpha Fund AIF newly disclosed 2.07% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of TTK Healthcare Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| T T Krishnamachari & Co. represented by its Partners -Mr T.T. Jagannathan and Mr T.T. Raghunnathan | 67.46% | unchanged |
| Abakkus Diversified Alpha Fund AIF | 2.07% | newly disclosed |
| SARAYU THIRUVALLUR THATTAI (Duly represented by Ms. Maitri Gopalakrishna, her Mother and Natural Guardian) | 1.89% | unchanged |
| Mukund Thiruvallur Thattai | 1.89% | unchanged |
| Tiruvallur Thatai Lakshman | 1.89% | unchanged |
| Jupiter India Fund Global fund house | 1.52% | unchanged |
| Investor Education and Protection Fund (IEPF) | 1.05% | unchanged |
| Shanthi Ranganathan | 0.41% | unchanged |
| Bhanu Raghunathan | 0.40% | unchanged |
| T T Raghunathan | 0.27% | unchanged |
| Latha Jagannathan | 0.21% | unchanged |
| Packwell Packaging Products Limited | 0.06% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
Growth trapTo justify its price of ₹1115, this stock must grow earnings at 25% every year for 7 years. Our analysis caps realistic growth at ~10%. At that growth it is worth ₹510 — downside of 54%.
- Growth the price implies
- 24.7% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 9.7% a year
- net profit, FY23–FY26 · EPS 9.6%
- The gap
- 0.2 pp
- -54% downside if it only repeats history
Learn to analyse TTK Healthcare Limited
Guides on how to read this kind of business and the numbers that matter.